Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Core Viewpoint - Shares of obesity drugmakers and developers experienced a decline following Novo Nordisk's forecast of a sharper-than-expected sales decline for 2026, highlighting increasing competition in the weight-loss market [1] Group 1 - Novo Nordisk's forecast indicates a significant sales decline for 2026, which was unexpected by the market [1] - The forecast reflects the intensifying competition within the obesity drug market, which is becoming increasingly crowded [1]